Latest News by Industry
![Karyopharm Therapeutics Inc. [KPTI] reports annual net loss of $143,099,000.0](/_next/image?url=https%3A%2F%2F10kinfo-appdata.s3.us-west-2.amazonaws.com%2Fedgar0105%2FCompanyLogos%2FUS%2FKPTI.png&w=1200&q=75)
Karyopharm Therapeutics Inc. [KPTI] has reported a net loss of $143,099,000.0 for year ended Dec 31, 2023.
The Company said in a filing before the Securities and Exchange Commission that its total revenue for the year was $146.0 million
Based in NEWTON, Massachusetts, Karyopharm Therapeutics Inc. operates in the MANUFACTURING sector.
In the Consolidated Statements of Operations for the 12 months ended December 31, we observe the following key financial figures:
- Revenues:
- 2023: $146.033 million
- 2022: $157.074 million
- 2021: $209.819 million
- Operating Expenses:
- 2023: Research and Development expenses totaled $138.750 million, while Selling, General and Administrative expenses amounted to $131.881 million, resulting in total operating expenses of $275.573 million.
- 2022: Research and Development expenses were $148.662 million, with Selling, General and Administrative expenses of $145.401 million, totaling $299.276 million in operating expenses.
- 2021: Research and Development expenses stood at $160.842 million, while Selling, General and Administrative expenses were $143.846 million, resulting in total operating expenses of $308.090 million.
- Net Loss:
- 2023: The company reported a net loss of $143.099 million.
- 2022: The net loss for the previous year was $165.291 million.
- 2021: In the corresponding period, the net loss amounted to $124.088 million.
- Earnings Per Share:
- Basic and Diluted earnings per share for 2023 were ($1.25).
- In 2022, both Basic and Diluted earnings per share were ($2.02).
- For 2021, the earnings per share for Basic and Diluted were ($1.65).
The results show a decrease in revenue from $157.074 million in 2022 to $146.033 million in 2023. Similarly, there was a decrease in net loss from $165.291 million in 2022 to $143.099 million in 2023. The earnings per share also improved from ($2.02) in 2022 to ($1.25) in 2023.
Also Read: